Evidence map›Paper›PMID 37700499›Full record

ReviewEuropean heart journal2023

Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases.

Dominik C Benz, Christoph Gräni, Panagiotis Antiochos, Bobak Heydari, Mark Colin Gissler, Yin Ge, Sarah A M Cuddy, Sharmila Dorbala, Raymond Y Kwong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Cardiovascular magnetic resonance for therapy monitoring in cardiomyopathies.European heart journal. Imaging methods and practice · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. An innovative hybrid imaging protocol for whole-bodyCardio-oncology (London, England) · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dominik C BenzNoninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Christoph GräniDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Panagiotis AntiochosCardiology and Cardiac MR Centre, University Hospital Lausanne, Lausanne, Switzerland.
Bobak HeydariCardiovascular Division, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Mark Colin GisslerDepartment of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Yin GeTerrence Donnelly Heart Center, St Michael's Hospital, Toronto, Canada.
Sarah A M CuddyNoninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Sharmila DorbalaNoninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Raymond Y KwongNoninvasive Cardiovascular Imaging Section, Cardiovascular Division, Department of Medicine and Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.ORCID 0000-0001-8212-0759

Funding

Personalized Exercise Training to Improve Functional Capacity in Transthyretin Cardiac AmyloidosisK23HL166686 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Sarah AM Cuddy · 2023 to 2026
$756k
NHLBI NIH HHS K23 HL166686Swiss National Science Foundation P400PM_199305
6 · The paper itself

Abstract

Cardiac magnetic resonance offers multiple facets in the diagnosis, risk stratification, and management of patients with myocardial diseases. Particularly, its feature to precisely monitor disease activity lends itself to quantify response to novel therapeutics. This review critically appraises the value of cardiac magnetic resonance imaging biomarkers as surrogate endpoints for prospective clinical trials. The primary focus is to comprehensively outline the value of established cardiac magnetic resonance parameters in myocardial diseases. These include heart failure, cardiac amyloidosis, iron overload cardiomyopathy, hypertrophic cardiomyopathy, cardio-oncology, and inflammatory cardiomyopathies like myocarditis and sarcoidosis.

Indexed as

CardiomyopathiesMyocarditisBiomarkersHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyProspective StudiesBiomarkersBiomarkerClinical trialCMREchocardiographyImagingPET

Identifiers

PMID37700499
PMCPMC11032206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.